Table 3 Antihypertensive medications use and risk of ovarian cancer mortality: lag time analyses
Antihypertensive medications use | Follow-up excluding first 2 years after diagnosis | ||
|---|---|---|---|
HR (95% CI)a | Deaths/ Cases, n | HR (95% CI)a | |
SNS-AH | |||
Non-use | 1.00 | 156/467 | 1.00 |
Use | 1.05 (0.61; 1.80) | 18/43 | 1.10 (0.58; 2.10) |
Diuretics | |||
Non-use | 1.00 | 134/410 | 1.00 |
Use | 1.03 (0.68; 1.56) | 40/100 | 1.01 (0.62; 1.65) |
Beta blockers | |||
Non-use | 1.00 | 116/366 | 1.00 |
Use | 1.43 (0.98; 2.08) | 58/144 | 1.47 (0.94; 2.29) |
Calcium channel blockers | |||
Non-use | 1.00 | 153/446 | 1.00 |
Use | 0.75 (0.45; 1.23) | 21/64 | 0.78 (0.44; 1.40) |
Angiotensin receptor blockers | |||
Non-use | 1.00 | 160/461 | 1.00 |
Use | 0.73 (0.43; 1.23) | 14/49 | 0.55 (0.29; 1.04) |
ACE inhibitors | |||
Non-use | 1.00 | 131/380 | 1.00 |
Use | 0.55 (0.36; 0.83) | 43/130 | 0.58 (0.37; 0.93) |